Pheochromocytoma Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Pheochromocytoma Market Trends and Insights

Rising Detection of Previously Unrecognized Tumors

Incidental identification is changing the pheochromocytoma market because many tumors are now found during imaging ordered for other conditions. The 2026 SEER analysis recorded a 5.8% annual increase in United States case counts from 1975 through 2022. A 2025 review argued that the often-cited incidence estimate of 1.9 cases per million person-years understates the number of cases identified as imaging access expands. A 2025 European congress report also found that annual PPGL incidence at 2 hospitals increased from 1.92 to 5.25 cases after 2020, and 51.9% of cases were identified incidentally. Imaging for other clinical indications, adrenal incidentaloma procedures, and post-COVID surveillance can therefore add patients without a dedicated PPGL screening campaign. This pattern supports demand for biochemical testing, functional imaging, surgical evaluation, and follow-up care across the pheochromocytoma market.

Expansion of Germline Genetic Testing and Cascade Screening

PPGL has a hereditary component in 30% to 40% of patients, which makes genetic evaluation more important than for many other solid tumors. The 2024 international consensus statement recommends germline testing for all pediatric PPGL patients and for first-degree relatives of confirmed mutation carriers^{[1]H. P. H. Neumann et al., “International Consensus Statement on the Diagnosis and Management of Pheochromocytoma and Paraganglioma in Children and Adolescents,” Nature Reviews Endocrinology, nature.com.}. This shifts practice away from limited, gene-by-gene testing toward broader evaluation when clinically appropriate. Each confirmed hereditary case can lead to testing of 2 to 5 relatives, followed by multigene sequencing and continued biochemical or imaging surveillance. A September 2025 study demonstrated the feasibility and clinical utility of germline multigene panel testing in Japanese PPGL patients. The hereditary segment’s 7.22% CAGR reflects guideline-driven testing and surveillance activity within the pheochromocytoma market, rather than an increase in mutation prevalence.

Growth in Precision Therapies for Molecularly Defined Disease

The FDA approved Merck’s belzutifan on May 14, 2025, for adult and pediatric patients aged 12 years and older with locally advanced, unresectable, or metastatic PPGL. In the LITESPARK-015 study, belzutifan achieved a 26% objective response rate and a median duration of response of 20.4 months. Belzutifan targets HIF-2α, which is relevant in VHL-driven disease and in a subset of sporadic Cluster 1 tumors. Evidence for other targeted therapies has also developed, with sunitinib reporting 12-month progression-free survival of 36% against 19% for placebo in FIRSTMAPPP. Cabozantinib reported a 25% objective response rate, median progression-free survival of 16.6 months, and median overall survival of 24.9 months in the NATALIE trial. These choices are increasing molecular profiling and specialist assessment across the pheochromocytoma market.

Radioligand Manufacturing and Theranostic Platform Investment

Radioligand therapy is becoming more relevant as imaging and treatment are linked through somatostatin receptor assessment. A 2026 study of 15 patients with metastatic PPGL who received 177Lu-DOTATATE reported a 27% objective response rate, a 73% disease control rate, median progression-free survival of 26.9 months, and median overall survival of 54.8 months. ITM’s COMPETE trial in advanced gastroenteropancreatic neuroendocrine tumors reported median progression-free survival of 23.9 months with 177Lu-edotreotide, compared with 14.1 months for everolimus. This result provides a clinical and manufacturing reference point for PPGL radiopharmaceutical programs. Capacity remains limited because beta-emitting radioligands are provided by a small group of specialized centers, while alpha-emitter supply remains at an earlier stage. Perspective Therapeutics commissioned a second cGMP facility in Somerset, New Jersey, during the fourth quarter of 2024 to expand 212Pb supply for its development programs. Investment in isotope supply and specialized facilities can determine whether clinical evidence converts into wider access in the pheochromocytoma market.

Ultra-Rare Population Limits Commercial Trial Scale

The small patient population limits trial enrollment, commercial scale, and the speed of evidence generation. The United States records nearly 2,000 new PPGL diagnoses each year, while a 2025 systematic review reported pooled global incidence of 1.9 cases per million person-years. FIRSTMAPPP was the first randomized controlled PPGL trial and required multinational enrollment over multiple years to evaluate its primary endpoint. Eligibility rules based on SDHB status, VHL pathway activity, or SSTR2 expression divide an already small population into smaller groups. This makes single-arm studies and surrogate endpoints more common in advanced disease development. The resulting evidence base can delay payer acceptance and keeps the pheochromocytoma market dependent on specialist centers that can participate in international trials.

Reimbursement Friction for Off-Label and Orphan Therapies

Orphan therapy pricing places manufacturers’ need to recover research costs against payer thresholds designed for more common diseases. A 2025 study of PPGL prescribing found that clinician knowledge of orphan-drug price increases affected the choice of therapy. Use of 177Lu-DOTATATE in PPGL may rely on compassionate access when its approved billing indication does not include PPGL, which can limit treatment to academic centers. Europe’s joint health technology assessment framework can add difficulty when an orphan therapy has supporting evidence from a single-arm study. Managed entry agreements are increasingly used to address evidence and reimbursement uncertainty for orphan medicines^{[2]E. Van Balen et al., “Drivers of Managed Entry Agreements for Orphan Medicinal Products,” Orphanet Journal of Rare Diseases, springer.com.}. These conditions can slow access within the pheochromocytoma market even where relevant imaging, medical expertise, and therapeutic capacity are available.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Offering: Treatment Remains the Largest Revenue Source While Diagnosis Expands Faster

Treatment held 64.31% of the pheochromocytoma market share in 2025, supported by adrenalectomy and perioperative pharmacological stabilization for patients with localized disease. Laparoscopic or robotic adrenalectomy remains a core approach, with preoperative alpha-adrenergic blockade supporting hemodynamic control. Radiopharmaceutical treatment is gaining importance as 177Lu-DOTATATE evidence develops for advanced PPGL. Belzutifan also opened a new systemic treatment option after its 2025 approval for unresectable and metastatic disease. Cyclophosphamide, vincristine, and dacarbazine chemotherapy retains a narrower role in inoperable hereditary disease, particularly in SDHB-mutated metastatic cases. Calcium channel blockers and beta-blockers remain useful adjuncts to alpha-blockade, but generic competition limits their revenue contribution.

Diagnosis is the fastest-growing offering, with the pheochromocytoma market size for diagnosis forecast to rise at a 5.58% CAGR from 2026 to 2031. Functional imaging with 68Ga-DOTATATE PET/CT and multigene sequencing panels are central to this expansion in the pheochromocytoma market. A 2024 scoping review reported that 68Ga-DOTA-SST PET/CT can identify more than 90% of lesions in patients without known germline variants. Panels covering SDHA, SDHB, SDHC, SDHD, VHL, RET, NF1, and TMEM127 are replacing sequential single-gene testing as testing costs decline. Testing of relatives after a hereditary diagnosis creates repeat laboratory and surveillance activity that does not depend on new disease incidence. Genetic counseling, consent, and disclosure requirements also create recurring contact with specialist programs.

By Disease Type: Improved Imaging Supports Faster Extra-Adrenal Detection

Adrenal pheochromocytoma held 83.44% of revenue in 2025 because adrenal tumors occur more often and follow a more established surgical pathway. Its biochemical workup commonly uses plasma fractionated metanephrines, which supports reproducible testing at tertiary centers. A Portuguese referral-center study published in 2024 recorded an incidence trend of 5.3 cases per million from 2012 through 2024. The study found metastatic disease only among hereditary cases, reinforcing the value of genetic assessment at diagnosis. Adrenal disease is expected to remain the majority disease type through 2031. Its share may narrow gradually as imaging identifies more lesions outside the adrenal gland.

Extra-adrenal pheochromocytoma and paraganglioma is forecast to grow at a 7.52% CAGR from 2026 to 2031 within the pheochromocytoma market. The 2024 scoping review reported 91% to 93% detection rates for 68Ga-DOTA-SST PET/CT in extra-adrenal and paraganglioma lesions without known germline variants. Limited 68Ga availability in Latin America shifts care toward 18F-FDOPA, which the same review associated with 74% detection efficiency. This difference shows how imaging capacity can influence local access to diagnosis. Head and neck paragangliomas are often non-secreting and may be identified later than other PPGL forms. Wider access to functional imaging is therefore important for the disease type’s faster growth.

By Etiology: Broader Testing Changes the Sporadic and Hereditary Mix

Sporadic etiology held 68.24% of revenue in 2025. This majority reflects the number of patients who had not been classified through a known inherited syndrome at the time of diagnosis. The segment’s share is expected to decline modestly as broader genetic evaluation reclassifies some cases. The 2024 international consensus statement supports germline testing for pediatric patients and first-degree relatives of known mutation carriers. Such guidance supports a more consistent testing approach across specialist care pathways. It also places clinical value on family history, genetic counseling, and lifelong surveillance.

Hereditary disease is the fastest-growing etiology segment, with a 7.22% CAGR from 2026 to 2031. Its growth is tied to increased panel testing and follow-up of first-degree relatives, rather than a change in mutation prevalence. A Japanese study published in September 2025 provided local evidence for the technical feasibility and clinical utility of germline panel testing. SDHB mutation carriers have a 30% to 40% lifetime risk of metastatic disease, which can increase their use of diagnostic and treatment services. European specialist networks concentrate hereditary care and support long-term biochemical and imaging schedules in the pheochromocytoma market. These repeated monitoring needs extend service use well beyond the initial diagnosis.

By Disease Stage: Advanced Disease Creates a Higher-Intensity Care Pathway

Localized disease accounted for 75.56% of the pheochromocytoma market size in 2025. This reflects the predominantly non-metastatic presentation of PPGL and the curative role of surgery for many patients. Laparoscopic adrenalectomy is a key treatment option for appropriate localized tumors, including tumors smaller than 6 cm under the Japanese guideline^{[3]Japan Endocrine Society, “Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025,” Endocrinology Journal, endocrj.org.}. Regional or locally advanced disease may require open surgery, debulking, and more intensive perioperative stabilization. Metyrosine can be considered for larger or invasive tumors that require additional catecholamine control. This care pattern remains central to the pheochromocytoma market.

Metastatic PPGL is forecast to expand at a 6.95% CAGR from 2026 to 2031 within the pheochromocytoma market. Before 2025, advanced care relied largely on off-label regimens and 131I-MIBG, with no approved systemic therapy for PPGL. Belzutifan and the 2025 Phase II study of 177Lu-DOTATATE have created more treatment options for progressive metastatic disease. This has increased the need to determine the sequence of targeted therapy, radionuclide treatment, and other systemic approaches. It also raises use of molecular profiling and functional imaging to assess SSTR2 expression. Advanced cases require specialized nuclear medicine, oncology, and endocrine support that is not available at every care site.

By End User: Specialty Centers Gain From Complex and Hereditary Care

Hospitals held 55.56% of end-user revenue in 2025 because they provide adrenal surgery, intensive perioperative care, and management of catecholamine-related complications. They remain essential for routine localized disease and acute presentation. Their position is supported by surgical teams, inpatient monitoring, imaging, and pharmacy services in one setting. Hospital revenue share may narrow as more complex hereditary and advanced cases move toward dedicated specialty programs. A 2025 study associated high-resource rare cancer centers with specialized genomic review and virtual multidisciplinary tumor boards with improved survival outcomes. Digital referral and tele-oncology tools may help patients reach these services when distance or insurance status limits access.

Specialty endocrinology centers are forecast to grow at a 6.65% CAGR from 2026 to 2031. These centers manage genetic counseling, cascade testing, biochemical surveillance, and coordination of referrals for peptide receptor radionuclide therapy. Cleveland Clinic reported that its PPGL Center of Excellence performs nearly 120 adrenal surgeries each year, compared with a national average of 1 surgery per general surgeon annually. This difference supports referral concentration for cases that need coordinated surgical and genetic expertise. Oncology centers also become more relevant as metastatic protocols use radiopharmaceutical and systemic therapy resources in the pheochromocytoma market. Nuclear medicine physics, radiation safety, and oncology pharmacy capabilities are particularly important for advanced care.

Geography Analysis

North America held 42.61% of the pheochromocytoma market share in 2025. The region benefits from high-volume academic referral centers, established reimbursement for 68Ga-DOTATATE PET/CT, and early commercial use of belzutifan after FDA approval in May 2025. United States care is increasingly concentrated in institutions that can provide functional imaging, SSTR2 assessment, radionuclide therapy, and radiation safety support. This can improve coordination for complex patients, but it can also concentrate capacity in a limited number of centers. Canada has a different access pattern because provincial formulary negotiations can trail United States approvals by 12 to 24 months. Perspective Therapeutics’ Somerset facility illustrates the concentration of alpha-particle radioligand supply infrastructure in the northeastern United States.

Europe represents a substantial part of the global pheochromocytoma market through national reference networks in Germany, France, and the United Kingdom. France’s COMETE network and other referral systems centralize multidisciplinary care and support longitudinal patient records. The EU joint clinical assessment framework can complicate access for therapies supported by single-arm orphan studies before national price negotiations take place. This process can add 12 to 18 months to effective access in the EU5. Spain, Italy, and Central and Eastern European countries may rely on compassionate access or named-patient programs for PPGL use of PRRT beyond the approved gastroenteropancreatic neuroendocrine tumor indication. These differences maintain an access gap among European health systems.

Asia-Pacific is the fastest-growing geography, with the pheochromocytoma market size projected to grow at a 6.85% CAGR from 2026 to 2031. Japan’s 2025 revised clinical guideline incorporated updated tumor classification, pediatric genetic testing recommendations, radionuclide therapy descriptions, and head and neck paraganglioma management. China’s oncology infrastructure and rising hereditary tumor awareness in India also support regional expansion in the pheochromocytoma market. Japan’s 131I-MIBG insurance coverage has provided a reimbursement precedent for later radionuclide therapy adoption. The Middle East, Africa, and South America remain limited by gaps in specialist and nuclear medicine capacity. Brazil has potential for further growth because of targeted oncology investment programs and greater genomic medicine funding.